U.S., April 8 -- ClinicalTrials.gov registry received information related to the study (NCT07513233) titled 'Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL)' on March 29.
Brief Summary: This study is an investigator-initiated Phase 1b clinical trial employing an open-label, non-randomized, dose-escalation design. The primary objective is to evaluate the safety and tolerability of the investigational intervention and to determine the recommended dose for subsequent clinical studies.
Study Start Date: April 15
Study Type: INTERVENTIONAL
Condition:
Acute Ischemic Stroke
Intervention:
DRUG: Anisodine Hydrobromide
Anisodine hydrobromide injection is administered intravenously in addit...